Clinical Trial Update: Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing polyglutamate paclitaxel with docetaxel in progressing non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• polyglutamate paclitaxel (not specified)

Snippet

Sponsor: CTI BioPharma | Conditions: Lung Cancer | Phase 3 | Status: TERMINATED